Nabriva Corporate
Go to...
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us
  • News & Publications
  • Careers
  • Contact Us
Nabriva Corporate
  • Home
  • About Nabriva
    • Our Products
    • Named Patient Program
    • Meet the Team
  • pipeline & research
    • Fosfomycin
    • pleuromutilins
  • For Investors
    • Events & Presentations
    • Press Releases
    • Financial Performance
    • Share Performance
    • Shareholder Information
    • Corporate Governance
  • News & Publications
  • careers
  • contact us

 

Driven to Deliver Innovative Treatments for Patients With Infectious Diseases

Nabriva Therapeutics is a commercial-stage biopharmaceutical company engaged in the development of innovative anti-infective agents to treat serious infections.
Learn More
  • PIPELINE &
    RESEARCH

    See Pipeline

PIPELINE & RESEARCH

Learn About Our Novel
Antibiotic Candidates

See Pipeline

  • FOR INVESTORS

    Visit Investors Center

FOR INVESTORS

Find Shareholder News,
Events, & More

Visit Investors Center

  • CAREERS

    View Jobs

CAREERS

Join Our Growing Team
at Nabriva

View Jobs

Collaborate With Us

 

We’re developing innovative therapies that have the potential to transform the lives of people with infectious diseases, and our current platform is just the beginning. We actively seek collaborators and licensing opportunities focused on the discovery, development, and commercialization of technologies and therapies that address infectious diseases. Contact us to learn more.

Contact Us

Nabriva Response to COVID-19

Thank you to all the healthcare professionals for your tireless service on the frontlines of this pandemic.  Due to COVID-19, the FDA has reported shortages of key drugs, including select antibiotics.  XenletaTM (lefamulin) may be an alternative regimen for patients in need.  Nabriva wants to reassure you that we have sufficient inventory of XENLETA IV and Oral tablets, available through designated specialty pharmacies or specialty distributors.  Learn more at www.XENLETA.com.

Again, to all the medical professionals, please be safe, take care of yourself and stay well.

Best,
Ted Schroeder
CEO, Nabriva Therapeutics

Continue to site

  • image of 3 people having a discussion and collaborating

    In the News

     

    Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

  • In the News

     

    Nabriva Therapeutics Granted New Technology Add-On Payment for XENLETA® (lefamulin) and CONTEPO™ (fosfomycin) by Centers for Medicare & Medicaid Services

  • In the News

     

    Nabriva Therapeutics Enters into Exclusive Agreement to Promote and Distribute SIVEXTRO® (tedizolid phosphate) in the U.S.

Nabriva logo
  • Privacy Notice
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland

  • Privacy Notice
  • Patents
  • Imprint
  • Disclaimer
  • Contact Us
  • Careers
  • Sitemap
Nabriva logo

© Nabriva Therapeutics plc, Ireland Registration No. 599588, 25-28 North Wall Quay, Dublin 1, Ireland